Enhertu first secured approval in 2019 for patients with high levels of HER2, a protein that promotes cancer cell growth. In ...

The FDA clearance aids AstraZeneca and Daiichi Sankyo’s plan to position ADCs like Enhertu ahead of chemotherapy in a variety ...

A phase 3 clinical trial has shown that adding a targeted immunotherapy drug to chemotherapy dramatically improved – almost ...

Roche has given two early-phase bispecifics the heave-ho, ending work on a HER2xCD3 prospect and an IL-15 candidate it picked up from Xencor. | Roche has given two early-phase bispecifics the heave-ho ...

The antibody drug conjugate was approved for patients with unresectable or metastatic HER2-low or -ultralow breast cancer ...

To treat your advanced HER2 negative breast cancer ... Chemotherapy drugs work by killing fast-growing cancer cells anywhere in your body. Chemotherapy may be given before surgery to shrink ...

The FDA has approved a new treatment for patients with a common form of breast cancer that has spread to other parts of the ...

Enhertu is a HER2-directed antibody and topoisomerase inhibitor conjugate. Approval of the new indication was based on data from the phase 3 DESTINY-Breast06 trial (ClinicalTrials.gov Identifier: ...

Among patients with advanced PIK3CA-mutated, HR-positive/HER2-negative breast cancer, Itovebi-based treatment generated positive overall survival results.

During a Case-Based Roundtable event, Laura Huppert, MD, reviewed antibody-drug conjugates for a patient with metastatic ...

Molecular oncology is revolutionizing cancer care by using genetic profiling to tailor personalized treatments, improving ...

The approval is based on findings from a phase 3 study which demonstrated the drug’s superiority over chemotherapy.